Opportunities for Enterprise

There are many ways for enterprise partners to engage with the research experts in the School of Biotechnology. Find further information below regarding collaborations or consultancy.

Collaboration Opportunities

Please contact any of the PIs below to find out further information.

The specialists in the Health Technologies and The Healthy and Ageing Society Hub’s business development team can arrange ready access to DCU’s patent portfolio and can help to create interactions with DCU researchers that are tailored to fit the specific needs of individual enterprises. For further information and opportunities for collaboration contact:

Prof Christine Loscher, Director, Health Technologies and Healthy & Ageing Society, Research & Enterprise Hub: Tel +353 1 700 5244. Email: christine.loscher@dcu.ie
Emma O’Neill, Business Development Manager, DCU Invent: Tel + 353 1 7007741 Email: emma.oneill@invent.dcu.ie
Fiona Brennan, Senior Research Support Officer, DCU Research & Innovation: Tel + 353 1 7007816 Email: fiona.brennan@dcu.ie

Dr. Phil Cummins: Availability (within the PI Lab) of an in vitro blood-brain barrier (BBB) model for pre-clinical assessment of food/drug compounds

Dr. Michael Freeley led a collaborative project with an international life sciences company where he performed the first RNAi library screens in primary human T-cells using their proprietary self-delivering RNAi technology (Freeley et al. 2015, J. Biomolecular Screening). He has also carried out contract research for a pharmaceutical company to screen small molecule drugs to evaluate their anti-inflammatory potential in in-vitro T-cell assays.

Further information about collaborative opportunities in DCU can be found HERE.

Consultancy

Prof Christine Loscher, Director, Health Technologies and Healthy & Ageing Society, Research & Enterprise Hub: Tel +353 1 700 5244. Email: christine.loscher@dcu.ie
Emma O’Neill, Business Development Manager, DCU Invent: Tel + 353 1 7007741 Email: emma.oneill@invent.dcu.ie
Fiona Brennan, Senior Research Support Officer, DCU Research & Innovation: Tel + 353 1 7007816 Email: fiona.brennan@dcu.ie

Prof. Paul Cahill: Vascular Biology, Stem Cell Biology, MechanoBiology, Cytomechanics, Pharmacology, Cardiovascular Disease. Prof. Cahill has been a consultant for Medtronic AVE, Bayer AG, IDA and SFI.

Dr. Greg Foley: Engineering design and analysis of membrane filtration systems, General mathematical modelling of processes.

Dr. Brid Quilty: Microbiological sample analysis, water and wastewater treatment, antimicrobial testing, photobiology

Dr. Jenny Lawler: Specification of membrane based solutions for water and wastewater treatment, development of tailored novel membranes for protein separation or environmental application.

Dr. Brendan O’Connor: Glycoprotein separation and analysis

Dr. Anne Parle-McDermott: Folic acid nutrition, Functional Genetics, PCR based assays.

Dr. Dermot Walls: Biological analysis of virus-host interactions, detection of pathogens, cell and molecular responses to products in vitro. Brochure link.

Prof. Richard O’Kennedy: Antibody and Immunosensor development. Training in antibody technologies, Protein Expression and Purification, Assay development

Dr. Michael Freeley: RNAi library screens in primary human T-cells using their proprietary self-delivering RNAi technology, screening small molecule drugs to evaluate their anti-inflammatory potential in in-vitro T-cell assays.

Further information:

DCU INVENT – Innovation & Enterprise

Health Technologies and the Healthy & Ageing Society

Information Technology and Digital Society

Sustainable Economies and Societies

CASE STUDIES:

Prof. Paul Cahill has previously worked with General Electric, Bristol Meyers Squibb, Medtronic AVE, Bayer Healthcare, Elan Pharmaceuticals Inc, Solvotrin Innovations Ltd.

Dr. Brendan O’Connor has worked extensively with Bristol Meyers Squibb, Agilent , Waters and Dionex. GlycoSelect Ltd. Is a spin-out company that has developed from work done in his group. Patent {EPO12188702.0-2403} is licensed to GlycoSelect.

Prof. Christine Loscher has significant partnerships with Irish biotech companies and Global food companies in the area of immunomodulation for health benefit.

Prof. Richard O’Kennedy has completed 40 projects for national and international industrial partners. He has licenced reagents, has a number of patents (licenced by industry) and provides a service for antibody generation and assay development.

Dr. Brid Quilty works closely with industry. Projects have included work with Merck in Ireland and Germany and BioFuture Ltd., Ireland. She is the external representative on the Biological Safety Committee, Pfizer, Grange Castle, Dublin and BMS, Cruiserath, Dublin.

Dr. Jenny Lawler: has partnered with companies including Alltech and Oxymem in the development of waste and water management soloutions.

Dr. Dermot Walls has worked with GlaxoSmithKline Plc., Proctor and Gamble, Enfer Group and Alltech (Ireland) on a variety of projects. He is a judge at the BT Young Scientist and Technology competition.

SPIN OUTS:

A number of spin-outs have arisen from the research of Prof. Richard O’Kennedy and Dr. Brendan O’Connor. These include GlycoSelct Ltd. Patent {EPO12188702.0-2403} is licensed to GlycoSelect. Prof. O’Kennedy is on the Scientific Board of Glycoselect and, in addition, is developing a service for antibody generation and commercialisation.

Further information: